The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials-Reference-Cited by-同舟云学术

The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials

Published:2017-05-30 Issue:6 Volume:69 Page:1257-1266
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Merrill Joan T.¹,Immermann Fred²,Whitley Maryann²,Zhou Tianhui²,Hill Andrew²,O'Toole Margot²,Reddy Padmalatha²,Honczarenko Marek²,Thanou Aikaterini¹,Rawdon Joe¹,Guthridge Joel M.¹,James Judith A.¹,Sridharan Sudhakar²

Affiliation:

1. Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences CenterOklahoma City

2. Pfizer, Inc.Cambridge Massachusetts

Funder

Oklahoma Medical Research Foundation

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40086

Reference35 articles.

1. Systemic Lupus Erythematosus

2. Systemic Lupus Erythematosus

3. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center

4. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus

5. Lupus: Key Pathogenic Mechanisms and Contributing Factors

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients;Clinical Rheumatology;2024-07-04

2. New and emerging therapies for systemic lupus erythematosus;Clinical Immunology;2024-06

3. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial;Arthritis & Rheumatology;2023-11-29

4. POS1154 PRE-TREATMENT DIFFERENTIALLY EXPRESSED METAGENES CHARACTERIZE SYSTEMIC LUPUS PATIENTS WHO SUBSEQUENTLY ACHIEVE CLINICAL RESPONSE TO BELIMUMAB;Scientific Abstracts;2023-05-30

5. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03